Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.58 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.49 |
| ▸ | TRIM58 | Q8NG06 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | DHODH | Q02127 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20294440 | 0.85 | CYP3A4 (0.50) | KDM4ECYP3A4CYP2C19HIF1APSMB5 | |
| SCHEMBL3499138 | 0.82 | NT5E (0.51) | KDM4ETRIM58LMNAALDH1A1MAPT | |
| SCHEMBL13312389 | 0.82 | CYP1A2 (0.63) | KDM4ECYP2C19PSMB5TRIM58LMNA | |
| SCHEMBL28181895 | 0.81 | PIK3CA (0.51) | KDM4ETRIM58LMNAALDH1A1MAPT | |
| SCHEMBL832589 | 0.80 | CYP1A2 (0.64) | KDM4ECYP3A4CYP2C19HIF1ALMNA | |
| SCHEMBL10763478 | 0.79 | PSMB5 (0.49) | KDM4EPSMB5TRIM58ALDH1A1DHODH | |
| SCHEMBL2538787 | 0.78 | KDM4E (0.66) | KDM4ECYP3A4CYP2C19HIF1ALMNA | |
| SCHEMBL2538783 | 0.78 | KDM4E (0.66) | KDM4ECYP3A4CYP2C19HIF1AALDH1A1 | |
| SCHEMBL28385754 | 0.77 | KDM4E (0.49) | KDM4ECYP3A4CYP2C19HIF1AALDH1A1 | |
| SCHEMBL17734598 | 0.76 | LMNA (0.54) | KDM4ECYP3A4CYP2C19HIF1ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030176314-A1 | Compounds for the treatment of pain | H. LUNDBECK A/S (DK) | 2003-09-18 | — | — | US | disclosed |
| US-20030139431-A1 | Guanidines which are agonist/antagonist ligands for neuropeptide FF (NPFF) receptors | H. LUNDBECK A/S (DK) | 2003-07-24 | — | — | US | disclosed |
| WO-2003026657-A1 | COMPOUNDS FOR THE TREATMENT OF PAIN | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 2003-04-03 | — | — | WO | disclosed |
| WO-2003026667-A1 | QUINAZOLINO- AND QUINOLINO- GUANIDINES AS LIGANDS FOR THE NEUROP EPTIDE FF (NPFF) RECEPTORS | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 2003-04-03 | — | — | WO | disclosed |
| EP-0016978-B1 | PROCESS FOR PREPARING NITRILES | SCHERING AKTIENGESELLSCHAFT (DE) | 1987-05-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176314-A1 | Compounds for the treatment of pain | NPFFR2, NPFFR1, OPRL1 | KDM4E 4560/4885CYP3A4 4583/4885CYP2C19 4185/4885 |
| US-20030139431-A1 | Guanidines which are agonist/antagonist ligands for neuropeptide FF (NPFF) receptors | NPFFR1, NPFFR2, SSTR3 | KDM4E 3447/4885CYP3A4 3929/4885CYP2C19 4362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.